GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Phase 2

Active, not recruiting

Conditions: HIV Infections

Interventions: Drug: Teropavimab
Drug: Antiretroviral Therapy
Drug: Zinlirvimab
Drug: Lenacapavir Injection
Drug: Lenacapavir Tablet

First Posted Date: 2023-02-15

Last Posted Date: 2024-07-15

Lead Sponsor: Gilead Sciences

Target Recruit Count: 83

Registration Number: NCT05729568

Locations: 🇺🇸
Ruane Clinical Research Group, Inc., Los Angeles, California, United States
🇺🇸
Can Community Health Care, Fort Lauderdale, Florida, United States
🇺🇸
Emory University Hospital Midtown Infectious Disease Clinic, Atlanta, Georgia, United States

and more 30 locations

Study of Obeldesivir in Nonhospitalized Participants With COVID-19

Phase 3

Completed

Conditions: COVID-19

Interventions: Drug: Obeldesivir Placebo
Drug: Obeldesivir

First Posted Date: 2023-02-08

Last Posted Date: 2024-02-07

Lead Sponsor: Gilead Sciences

Target Recruit Count: 2011

Registration Number: NCT05715528

Locations: 🇺🇸
Innovative Health, Hollywood, Florida, United States
🇺🇸
Palm Springs Community Health Center, Miami Lakes, Florida, United States
🇺🇸
Institute for Liver Health dba Arizona Clinical Trials, Chandler, Arizona, United States

and more 102 locations

Study of Bulevirtide in Participants With Chronic Hepatitis D Infection

Recruiting

Conditions: Chronic Hepatitis D Infection

Interventions: Drug: Bulevirtide

First Posted Date: 2023-02-08

Last Posted Date: 2024-12-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 170

Registration Number: NCT05718700

Locations: 🇪🇸
Hospital Universitari Vall d'Hebrón, Barcelona, Spain
🇪🇸
Hospital Clinic de Barcelona, Barcelona, Spain
🇪🇸
Hospital Universitario Reina Sofía, Córdoba, Spain

and more 49 locations

Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Advanced Non-Small Cell Lung Cancer

Interventions: Drug: Domvanalimab
Drug: Quemliclustat
Drug: Zimberelimab
Drug: Platinum-Based Doublet
Drug: Docetaxel

First Posted Date: 2023-01-09

Last Posted Date: 2024-11-12

Lead Sponsor: Gilead Sciences

Target Recruit Count: 320

Registration Number: NCT05676931

Locations: 🇮🇹
Azienda Sanitaria Territoriale Pesaro Urbino (AST PU), Pesaro, Italy
🇮🇹
Fondazione IRCCS Istituto Nazionale dei tumori di Milano, Rome, Italy
🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

and more 49 locations

Study of Novel Treatment Combinations in Patients With Lung Cancer

Phase 2

Recruiting

Conditions: Lung Cancer
Resectable Non-Small-Cell Lung Cancer
Advanced or Metastatic Non-Small-Cell Lung Cancer

Interventions: Drug: Zimberelimab (ZIM)
Drug: Domvanalimab (DOM)
Drug: Carboplatin
Drug: Sacituzumab govitecan-hziy (SG)
Drug: Docetaxel
Drug: Etrumadenant (ETRUMA)
Drug: Cisplatin
Drug: Pemetrexed
Drug: Nivolumab
Drug: Paclitaxel
Drug: Nab-paclitaxel

First Posted Date: 2022-12-01

Last Posted Date: 2024-11-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 593

Registration Number: NCT05633667

Locations: 🇧🇷
Hospital Mae de Deus, Porto Alegre, Brazil
🇧🇷
Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03, Porto Alegre, Brazil
🇬🇧
Birmingham Heartlands Hospital,Substudy-03, Birmingham, United Kingdom

and more 80 locations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

Phase 3

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Sacituzumab govitecan-hziy (SG)
Drug: Pembrolizumab
Drug: Capecitabine

First Posted Date: 2022-12-01

Last Posted Date: 2024-11-27

Lead Sponsor: Gilead Sciences

Target Recruit Count: 1514

Registration Number: NCT05633654

Locations: 🇺🇸
Alabama Oncology, Birmingham, Alabama, United States
🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸
Northwestern Medicine, Chicago, Illinois, United States

and more 162 locations

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Phase 2

Recruiting

Conditions: Cutaneous Lupus Erythematosus (CLE)

Interventions: Drug: Edecesertib
Drug: Edecesertib Placebo

First Posted Date: 2022-11-29

Last Posted Date: 2024-12-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 33

Registration Number: NCT05629208

Locations: 🇺🇸
University of Colorado, Barbara Davis Center, Center for Clinical Research, Aurora, Colorado, United States
🇺🇸
ARENSIA Exploratory Medicine, LLC, Phoenix, Arizona, United States
🇺🇸
Center for Dermatology Clinical Research Inc., Fremont, California, United States

and more 28 locations

US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Relapsed/Refractory Acute Myeloid Leukemia

First Posted Date: 2022-11-25

Last Posted Date: 2024-02-15

Lead Sponsor: Gilead Sciences

Registration Number: NCT05627466

Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

Phase 3

Terminated

Conditions: COVID-19

Interventions: Drug: Obeldesivir
Drug: Obeldesivir Placebo

First Posted Date: 2022-11-02

Last Posted Date: 2024-12-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 468

Registration Number: NCT05603143

Locations: 🇵🇹
Hospital CUF Descobertas, Lisboa, Portugal
🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇧🇬
Diagnostic and Consulting Center Aleksandrovska EOOD, Sofia, Bulgaria

and more 78 locations

Study of Novel Antiretrovirals in Participants With HIV-1

Phase 1

Completed

Conditions: HIV-1-infection

Interventions: Drug: B/F/TAF
Drug: bavtavirine
Drug: GS-1720
Drug: GS-6212
Drug: Standard of Care (Substudy 01)
Drug: Standard of Care (Substudy 02)
Drug: Standard of Care (Substudy 03)

First Posted Date: 2022-10-18

Last Posted Date: 2024-08-01

Lead Sponsor: Gilead Sciences

Target Recruit Count: 49

Registration Number: NCT05585307

Locations: 🇺🇸
Washington Health Institute,Substudy-02, Washington, District of Columbia, United States
🇺🇸
Washington Health Institute,Substudy-01, Washington, District of Columbia, United States
🇺🇸
Washington Health Institute,Substudy-03, Washington, District of Columbia, United States

and more 39 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy